Clinical & experimental findings

Human randomized studyAbstract inspected

In a 1991 randomized, double-blind, six-month trial of 109 elderly patients with mild-to-moderate probable Alzheimer-type dementia, aniracetam produced a statistically significant improvement in psychobehavioral ratings compared with both baseline and a placebo group that steadily worsened. It provides no direct evidence for improving cognition in healthy people.^[1]

Older dementia trial; abstract lacks numeric effect sizes and detailed adverse-event reporting.
No independent systematic review or meta-analysis specific to aniracetam in dementia was located in this search; this rests on a single trial without independent corroboration identified.
Abstract-checked; no qualified clinical review.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-08 · Prior batch record retained as unverified historical input pending fresh review.

2026-09-09 · nootropic batch: reopened source(s) via NCBI E-utilities / PMC Open Access; verified and refined with precise numbers/limitations from the source.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Narrowly supported passages published with study/product limits; remaining inherited assertions withheld from established-fact displays.

Not a comprehensive systematic review. Original monograph topics beyond the individual published claims—including monitoring schedules, contraindication lists, recovery assurances and detailed mechanisms—remain unverified.
No qualified clinician has reviewed these claims. Long-term outcomes and all marketed formulations have not been fully assessed.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study.
Senin U, Abate G, Fieschi C, Gori G, Guala A, Marini G, Villardita C, Parnetti L. Eur Neuropsychopharmacol. 1991 Dec;1(4):511-7. DOI: 10.1016/0924-977X(91)90004-E. 1991-12. PMID:1822317 · DOI:10.1016/0924-977x(91)90004-e Abstract only.
Inspected location: PubMed/MEDLINE abstract (full Results/Methods text) via NCBI E-utilities efetch
Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts

Fresh PubMed EUtils retrieval for inherited lead PMID 1822317; identity, abstract and linked corrections checked where an abstract existed.
https://pubmed.ncbi.nlm.nih.gov/1822317/ — abstract; PubMed abstract: Treatment comparison and psychobehavioral results in probable Alzheimer-type dementia

View this compound in the research library →

Related records in this class

Grouped under Other compounds for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.